Evidence map›Paper›PMID 40495370›Full record

ArticleBritish journal of haematology2025

Temporal patterns in US population-based patient survival among adults treated with chemotherapy and/or immunotherapy for multiple myeloma, 2000-2020.

Graça M Dores, Jacqueline B Vo, Sara J Schonfeld, Jaimie Z Shing, Kekoa Taparra, Lindsay M Morton, Rochelle E Curtis, Martha S Linet

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Graça M DoresDivision of Cancer Epidemiology and Genetics, Radiation Epidemiology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-3985-2935
Jacqueline B VoDivision of Cancer Epidemiology and Genetics, Radiation Epidemiology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Sara J SchonfeldDivision of Cancer Epidemiology and Genetics, Radiation Epidemiology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Jaimie Z ShingDivision of Cancer Epidemiology and Genetics, Infections and Immunoepidemiology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Kekoa TaparraDepartment of Radiation Oncology, Stanford Medicine, Stanford, California, USA.
Lindsay M MortonDivision of Cancer Epidemiology and Genetics, Radiation Epidemiology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Rochelle E CurtisDivision of Cancer Epidemiology and Genetics, Radiation Epidemiology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Martha S LinetDivision of Cancer Epidemiology and Genetics, Radiation Epidemiology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

Funding

Multidisciplinary Studies of LymphomaZIACP010170 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MORTON, LINDSAY · 2009 to 2025
$10.7M
Intramural NIH HHS ZIA CP010170NCI NIH HHSNIH HHS
6 · The paper itself

Abstract

Few population-based studies have rigorously evaluated overall survival (OS) differences among adults treated with chemotherapy and/or immunotherapy (chemo/immunotherapy) for multiple myeloma (MM) during the past two decades when the therapeutic landscape substantially evolved. We evaluated OS among 50 288 adults diagnosed with MM between 2000 and 2019 reported to have received initial chemo/immunotherapy. We calculated hazard ratios (HRs) using multivariable Cox regression to compare OS across calendar periods and within patient demographic groups. OS improved over time (2000-2004 = reference; HR

Indexed as

ImmunotherapyMultiple MyelomaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedSurvival RateUnited Stateschemoimmunotherapyepidemiologylymphoid malignanciesmyelomasurvival

Identifiers

PMID40495370
PMCPMC12354210

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.